Targeting Signaling Pathways In Cancer Therapy

摘要

The clinical results of treatment with traditional chemotherapy for most solid tumor malignancies have remained disappointing over the last decades. Toxicities are often prohibitive. This demands the development of innovational, systemic treatment approaches. Small-molecule tyrosine kinase inhibitors (sm-TKIs) have shown promising results in several malignancies. We are reviewing the current progress of cancer therapy with sm-TKIs in solid tumor malignancies with a focus on breast cancer, hepatocellular cancer, colon cancer, and nonsmall-cell lung cancer and place this progress into the context of improvements in recent, targeted antineoplastic therapies.